|
|
|
| Application of Zhibitai Capsules for peritoneal dialysis |
| KONG Aili QIU Xiaoling |
| Department of Nephrology, Huludao Central Hospital, Liaoning Province, Huludao 125001, China |
|
|
|
Abstract Objective To investigate the effect of Zhibitai Capsules on serum lipids, inflammatory factors and oxidation stress indexes in peritoneal dialysis patients. Methods A total of 85 patients with peritoneal dialysis admitted to Huludao Central Hospital of Liaoning Province from January 2018 to December 2019 were selected. According to random number table method, 42 cases were divided into control group and 43 cases were observed group, routine treatment was given to both groups, and Zhibitai Capsules was added to the observation group. After treatment for six months three, the acyl glycerin (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and inflammatory factor, interleukin 6 (IL-6) and IL-8, hypersensitive C-reactive protein (hs-CRP), and oxidative stress indicators superoxide dismutase (SOD), malondialdehyde (MDA) and glutathione (GSH) levels were compared between the two groups. Results In the control group, TG, TC, LDL-C, IL-6, IL-8, hs-CRP were higher than before treatment, and HDL-C was lower than before treatment; in the observation group, TG, TC, LDL-C, IL-6, IL-8, hs-CRP were lower than before treatment, and HDL-C was higher than before treatment. After treatment, TG, TC, LDL-C, IL-6, IL-8 and hs-CRP in observation group were lower than those in control group, and HDL-C was higher than those in control group (P ＜ 0.05). After treatment, SOD and GSH of the two groups were increased and MDA was decreased (P ＜ 0.05), SOD and GSH in observation group were higher than those in control group, and MDA in observation group was lower than that in control group (P ＜ 0.05). Conclusion Zhibitai Capsules could benefit from the regulation of blood lipid level of dialysis patients, and improve the level of inflammatory factors and oxidation stress indexes.
|
|
|
|
|
|
[1] Segall L，Nistor I，Van Biesen W，et al. Dialysis modality choice in elderly patients with end-stage renal disease：a narrative review of the available evidence [J]. Nephrol Dial Transplant，2017，32（1）：41-49.
[2] Jagdale A，Cooper DKC，Iwase H，et al. Chronic dialysis in patients with end-stage renal disease：Relevance to kidney xenotransplantation [J]. Xenotransplantation，2019，26（2）：e12471.
[3] Ji AD，Pan CL，Wang HX，et al. Prevalence and Associated Risk Factors of Chronic Kidney Disease in an Elderly Population from Eastern China [J]. Int J Environ Res Public Health，2019，16（22）：4383.
[4] Zazzeroni L，Pasquinelli G，Nanni E，et al. Comparison of Quality of Life in Patients Undergoing Hemodialysis and Peritoneal Dialysis：a Systematic Review and Meta-Analysis [J]. Kidney Blood Press Res，2017，42（4）：717-727.
[5] Niang A，Iyengar A，Luyckx VA. Hemodialysis versus peritoneal dialysis in resource-limited settings [J]. Curr Opin Nephrol Hypertens，2018，27（6）：463-471.
[6] Khan S，Rosner MH. Peritoneal Dialysis for Patients with End-Stage Renal Disease and Liver Cirrhosis [J]. Perit Dial Int，2018，38（6）：397-401.
[7] Wanner C，Tonelli M. Kidney Disease：Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD：summary of recommendation statements and clinical approach to the patient [J]. Kidney Int，2014，85（6）：1303-1309.
[8] Han QL，Zhang DX，Mao RY，et al. Research on the prevalence of chronic kidney disease and risk factors in northern populations of China [J]. Int J Clin Exp Med，2018，11（8）：8585-8592.
[9] Ferro CJ，Mark PB，Kanbay M，et al. Lipid management in patients with chronic kidney disease [J]. Nat Rev Nephrol，2018，14（12）：727-749.
[10] Lu R，Estremadoyro C，Chen X，et al. Hemodialysis versus peritoneal dialysis：an observational study in two international centers [J]. Int J Artif Organs，2017.
[11] Cicero AFG，Fogacci F，Banach M. Red Yeast Rice for Hypercholesterolemia [J]. Methodist Debakey Cardiovasc J，2019，15（3）：192-199.
[12] 赵磊，王子豪，隆歆然，等.红曲产品对高血脂症小鼠血脂的调节作用[A].中国食品科学技术学会第十六届年会暨第十届中美食品业高层论坛论文摘要集中国食品科学技术学会会议论文集[C].2019年.
[13] 路帅，郭建利，彪雅宁，等.丹参、泽泻对非酒精性脂肪肝大鼠氧化应激和血管内皮的影响[J].亚太传统医药，2020，16（10）：38-40.
[14] 楼陆军，罗洁霞，高云.山楂的化学成分和药理作用研究概述[J].中国药业，2014（3）：92-94.
[15] 唐琪晶，陈素红，潘丹丹，等.白术精提物对代谢性高脂血症大鼠的药效及机制研究[J].中国中药杂志，2015， 40（9）：1803-1807.
[16] 中国心脏联盟，中国康复医学会心脏预防与康复专业委员会，脂必泰胶囊临床应用中国专家共识组.脂必泰胶囊临床应用中国专家共识[J].中华内科杂志，2017， 56（8）：628-632.
[17] Wu J，Guo N，Chen X，et al. Coexistence of micro-inflammatory and macrophage phenotype abnormalities in chronic kidney disease [J]. Int J Clin Exp Pathol，2020， 13（2）：317-323.
[18] 周长菊，曹娟，章旭，等.微炎症状态和蛋白能量消耗在维持性腹膜透析人群中的特点[J].重庆医学，2017，46（23）：3212-3215，3218.
[19] 王江.脂必泰胶囊辅治对腹膜透析患者血脂水平的影响[J].临床合理用药，2020，13（4）：80-81.
[20] 熊敏.脂必泰胶囊对高脂血症患者血脂指标及炎症反应的影响[J].中国处方药，2019，17（12）：108-109.
[21] 董畅.脂必泰联合他汀对冠心病患者血脂和炎症影响的Meta分析[D].沈阳：辽宁中医药大学，2019.
[22] 谭斌.阿托伐他汀钙片联合脂必泰治疗冠心病合并高脂血症的效果[J].当代医学，2020，26（3）：9-11.
[23] Stepanova N，Korol L，Burdeyna O. Oxidative Stress in Peritoneal Dialysis Patients：Association with the Dialysis Adequacy and Technique Survival [J]. Indian J Nephrol，2019，29（5）：309-316.
[24] 李蔚，夏平，周瑶，等.腹膜透析氧化应激损伤研究进展及中药干预作用[J].现代中医临床，2019，26（6）：72-76.
[25] 嵇志红.白术水提物对血管性痴呆大鼠学习记忆及皮层SOD、MDA含量的影响[J].大连大学学报，2017，38（6）：73-76.
[26] 高志强，谢美娟，陈立波.山楂果叶对脂肪肝大鼠脂质代谢及氧化应激的影响[J].四川中医，2016，34（5）：50-53. |
|
|
|
